BioSpace News Archive

Glenmark signs full commercial-use license for Horizon’s gene-edited CHO cells

Merck, known as MSD outside the United States and Canada, announced that the pivotal Phase 3 RECARBRIO™ RESTORE-IMI 2 trial met its primary endpoint.

SmartPharm Therapeutics announced that José Trevejo, MD, PhD, President and Chief Executive Officer, will present at the Chardan 3rd Annual Genetic Medicines Conference on Monday, October 7 at 8:00 a.m. ET in New York City.

BiomX Ltd. announced that BiomX’s Chief Executive Officer, Jonathan Solomon, will present at the Cantor Fitzgerald Global Healthcare Conference in New York on Wednesday, October 2nd, at 8:55am ET.

Pursuit Vascular, Inc., manufacturer of ClearGuard® HD Antimicrobial Barrier Caps, announced it will be exhibiting at this week’s National Renal Administrators Association 2019 Annual Conference.

Insulet Corporation announced plans to release its financial results for the third quarter of 2019 on November 5, 2019 after the close of the financial markets.

22% Response Rate; 61% Disease Control Observed

Bloom Burton & Co. is pleased to announce Dr. Poul Sorensen as the recipient of the 2019 Bloom Burton Award.

AVEO Oncology announced that it has initiated enrollment in an open-label, multi-center Phase 1b/2 clinical trial evaluating FOTIVDA®, the Company’s once-daily, potent and selective vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with IMFINZI®, AstraZeneca’s human monoclonal antibody directed against programmed death-ligand 1, in patients with hepatocellular carcinoma who have not received prior systemic therapy.

Ocugen, Inc., announced the completion of its merger with Histogenics Corporation, and the change of the combined company’s name to “Ocugen, Inc.” Ocugen is expected to begin trading on The Nasdaq Capital Market under the ticker symbol “OCGN.” The executive team of Ocugen has become the executive team of the combined company, led by Shankar Musunuri, Ph.D., M.B.A., as Chairman, Chief Executive Officer and Co-Founder.